Athira Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATHA research report →
Companywww.athira.com
Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease.
- CEO
- Mark J. Litton
- IPO
- 2020
- Employees
- 26
- HQ
- Bothell, WA, US
Price Chart
Valuation
- Market Cap
- $26.62M
- P/E
- -1.40
- P/S
- 0.00
- P/B
- 3.66
- EV/EBITDA
- -0.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -381.01%
- ROIC
- -168.10%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-105,609,000 · -8.94%
- EPS
- $-24.70 · 1.98%
- Op Income
- $-102,266,000
- FCF YoY
- 52.96%
Performance & Tape
- 52W High
- $8.36
- 52W Low
- $2.20
- 50D MA
- $5.48
- 200D MA
- $4.03
- Beta
- 2.80
- Avg Volume
- 1.06M
Get TickerSpark's AI analysis on ATHA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 21 | CHURCH KEVIN | other | 3,152 |
| May 18, 21 | CHURCH KEVIN | other | 185 |
| Jun 8, 21 | CHURCH KEVIN | other | 3,152 |
Our ATHA Coverage
We haven't published any research on ATHA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ATHA Report →